Last reviewed · How we verify
Unresectable advanced or recurrent esophageal cancer — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Yervoy | Yervoy | Bristol-Myers Squibb | Cytotoxic T-lymphocyte protein 4 | |||
| Yervoy | ipilimumab | Bristol-Myers Squibb | CTLA-4-directed Blocking Antibody | Cytotoxic T-lymphocyte protein 4 | 2011-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 2 drugs in Unresectable advanced or recurrent esophageal cancer
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Unresectable advanced or recurrent esophageal cancer:
- Unresectable advanced or recurrent esophageal cancer treatment updates — RSS
- Unresectable advanced or recurrent esophageal cancer treatment updates — Atom
- Unresectable advanced or recurrent esophageal cancer treatment updates — JSON
Cite this brief
Drug Landscape (2026). Unresectable advanced or recurrent esophageal cancer — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/unresectable-advanced-or-recurrent-esophageal-cancer. Accessed 2026-06-10.
Related
- Unresectable advanced or recurrent esophageal cancer full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing